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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with 
over 550,000 new cases diagnosed each year (1). Human papillomavirus (HPV) infection causes a subset 
of  HNSCCs that present with distinct clinical, pathological, and molecular features compared with the 
HPV-negative disease, which is typically associated with tobacco and alcohol use (2, 3).
Smoking history at the time of  diagnosis is considered an important negative prognostic factor for both 
HPV-positive and -negative HNSCCs (4–6). Given the observed differences in outcomes based on smoking 
status, there is interest in understanding the molecular differences between never smokers and smokers in 
both HPV-positive and -negative diseases. A previous study by Yavorski and colleagues examined differenc-
es in mutation frequencies by smoking status in several smoking related cancers including lung, head and 
neck, pancreatic, and bladder cancer, using data from The Cancer Genome Atlas (TCGA) (7). They iden-
tified a difference in the frequency of  single nucleotide variations (SNVs) associated with the cytoskeletal 
protein–related coding regions (CPRCRs) in both lung and head and neck cancers, as well as differential 
SNV rates in cancer driver genes in lung cancer. However, the investigators a priori limited their analysis to 
CPRCRs, tumor suppressors, and oncogenes, limiting the discovery potential of  the study (7). Moreover, 
HNSCC data was not stratified by HPV status, which is another significant shortcoming.
Recently, Bratman and colleagues reanalyzed TCGA’s HNSCC RNA sequencing database for the 
presence of  HPV transcripts to definitively identify the HPV status of  each patient (8). Building on this 
Smoking has historically been recognized as a negative prognostic factor in head and neck 
squamous cell carcinoma (HNSCC). This study aimed to assess the mutational differences between 
heavy smokers (>20 pack years) and never smokers among the HNSCC patients within The Cancer 
Genome Atlas (TCGA). Single nucleotide variation and copy number aberration differences between 
heavy smokers and never smokers were compared within human papillomavirus–positive (HPV-
positive) (n = 67) and HPV-negative (n = 431) TCGA cohorts with HNSCC, and the impact of these 
mutations on survival were assessed. No genes were differentially mutated between smoking and 
never-smoking patients with HPV-positive tumors. By contrast, in HPV-negative tumors, NSD1 
and COL1A11 were found to be more frequently mutated in heavy smokers, while CASP8 was more 
frequently altered in never smokers. HPV-negative patients with NSD1 mutations experienced 
significantly improved overall survival compared with NSD1 WT patients. This improved prognosis 
was validated in an independent cohort of 77 oral cavity cancer patients and a meta-analysis that 
included 2 additional data sets (688 total patients, hazard ratio for death 0.44, 95% CI, 0.30–0.65). 
NSD1 mutations are more common in HPV-negative heavy smokers, define a cohort with favorable 
prognosis, and may represent a clinically useful biomarker to guide treatment deintensification for 
HPV-negative patients.
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new information, we have comprehensively explored the differences between the clinical characteristics, 
prognosis, and mutational profile of  HPV-positive and -negative tumors within TCGA HNSCC data set, 
stratified by patients’ smoking history.
Results
NSD1, CASP8, and COL1A11 mutations were associated with smoking in HPV-negative HNSCC. TCGA HNSCC 
cohort comprised 431 HPV-negative and 67 HPV-positive primary HNSCC samples with DNA mutation and 
survival information. Within the HPV-negative group, there were 205 heavy smokers and 90 never smokers. 
In the HPV-positive group, 21 of  the patients were heavy smokers and 23 were never smokers. Patient demo-
graphic differences between heavy smokers and never smokers are provided in Supplemental Table 1 (supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.123443DS1).
The total SNV mutational load was significantly lower in HPV-positive patients (median = 72, 95% 
CI, 57–95) compared with HPV-negative patients (median = 110.5, 95% CI, 106–117; P = 0.0001, Supple-
mental Figure 1A). The correlation between total mutation count and pack year history of  smoking was 
significant in HPV-negative patients (Spearman’s Rho = 0.28, 95% CI, 0.18–0.38, P < 0.0001) but not in 
HPV-positive patients (Spearman’s Rho = 0.05, 95% CI, –0.21–0.31, P = 0.68; Supplemental Figure 1B).
A comparison of  SNVs in individual genes identified no significant differences between never smoker 
and heavy smoker samples in the HPV-positive group following correction for multiple hypothesis testing 
(Supplemental Figure 2). In contrast, the frequency of  SNVs in NSD1, CASP8, and COL11A1 between the 
never smokers and heavy smokers in the HPV-negative group was significantly different (Figure 1).
The frequency of  NSD1 mutations in HPV-negative light smokers (≤ 20 pack year) was greater than that 
of  never smokers but less than that of  heavy smokers (2.22% never smokers, 4.55% light, and 18.5% heavy 
smokers, respectively; Supplemental Table 2). The opposite pattern was seen for CASP8 and COL11A1 
(Supplemental Table 2). The occurrence rates stratified by smoking status for all 3 genes were similar to 
those Stransky et al. reported (ref. 9 and Supplemental Table 2). Lists of  the 100 most differentially mutat-
ed genes, based on smoking history, in HPV-positive and -negative patients are provided in Supplemental 
Tables 3 and 4, respectively.
Analysis of  copy number aberrations (CNAs) did not reveal any statistically significant differences in 
large amplifications (e.g., amplifications larger than the arm-level amplifications observed for the sample; 
ref. 10) or deep deletions based on smoking status in either the HPV-positive or -negative subsets after FDR 
correction (Supplemental Table 5).
NSD1 mutations were associated with improved overall survival in HPV-negative patients. There was no signif-
icant difference in overall survival between the never smokers and heavy smokers in either the HPV-posi-
tive or HPV-negative cohorts (Supplemental Figure 3 and Supplemental Table 6). However, in HPV-nega-
tive patients, those with NSD1 mutations experienced superior overall survival compared with NSD1 WT 
patients (Figure 2A and Supplemental Table 6). The impact of  NSD1 mutation on survival within the entire 
TCGA HNSCC tumor cohort (n = 498, 55 NSD1 mutations) was comparable to that of  HPV status (n = 67 
HPV positive; hazard ratios [HRs] in Supplemental Figure 4). By contrast, mutations in CASP8 or COL11A1 
were not associated with significant survival differences (Supplemental Figure 5). NSD1 functions as an H3 
histone lysine 36 (H3K36) methyltransferase, and NSD1-mutant tumors exhibited an altered global DNA 
methylation pattern that was recapitulated in tumors with H3K36M mutations (10). Importantly, H3K36M 
mutation status was not correlated with overall survival (log-rank P = 0.99), ruling out a role for altered 
DNA methylation in the survival advantage associated with NSD1 mutation (Supplemental Figure 6).
Targeted sequencing of  NSD1 in an independent cohort of  77 oral cavity cancers also demonstrated 
improved overall survival for patients with NSD1 mutations in a multivariable survival model (P < 0.05, 
Figure 2B and Supplemental Table 7). We carried out a meta-analysis of  4 available data sets, including 
TCGA data set, Bui et al. (11), Peri et al. (12), and our validation cohort, comparing survival by NSD1 
mutation status. The pooled estimate for these studies demonstrated strong evidence for improved overall 
survival for patients with NSD1-mutant tumors compared with patients with WT tumors (Figure 3, HR 
0.44; 95% CI, 0.30–0.65; P < 0.0001). There was no evidence of  heterogeneity (P = 0.61, I2 = 0%). A sen-
sitivity analysis was performed, excluding incomplete data; this did not significantly change the pooled HR 
estimate (HR 0.40; 95% CI, 0.26–0.62; P < 0.0001).
NSD1 mutations were associated with mutations in ECM genes. In TCGA HPV-negative cohort, NSD1-mu-
tant tumors were associated with a heavier smoking history and were more prevalent in the laryngeal 
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subsite compared with NSD1 WT tumors (Supplemental Table 8). In TCGA HPV-negative patients, total 
mutational load was higher in NSD1-mutant (median = 209, 95% CI, 163–336) tumors relative to NSD1 WT 
tumors (median = 105.5, 95% CI, 100–110), and this difference was statistically significant (Mann-Whit-
ney U test, P < 0.0001). Comparison of  gene-wise mutation status between NSD1-mutant and WT tumors 
revealed 180 genes to be mutated at different frequencies (FDR < 0.01; Figure 4). A list of  the top 100 
differentially mutated genes between NSD1-mutant and WT HPV-negative HNSCC samples is provided in 
Supplemental Table 9. Pathway analysis with these differentially mutated genes revealed multiple overrep-
resented pathways (top 20 overrepresented pathways in Supplemental Table 10), suggesting a potentially 
altered ECM environment in the NSD1-mutant compared with NSD1 WT HPV-negative HNSCC tumors. 
Analysis with the top mutated genes in HPV-negative HNSCC showed that NSD1 mutations had a pattern 
of  co-occurrence with other highly mutated genes, and no mutually exclusive mutations were identified 
(Supplemental Table 11).
Discussion
We have identified genes with SNVs that occur at significantly different frequencies in HPV-negative heavy 
smokers and never smokers: NSD1 and COL1A11 (more frequent in smokers) and CASP8 (more frequently 
in never smokers; Figure 1). Importantly, NSD1 mutations were associated with improved survival, inde-
pendent of  smoking status. Indeed, our meta-analysis of  4 independent cohorts comprising 638 patients 
confirmed the strong survival advantage for patients with NSD1-mutant tumors (Figure 3). This survival 
difference was profound, with an HR comparable to the prognostic significance of  HPV (Supplemental 
Figure 4). Given these findings are reproducible across multiple independent data sets, it is likely that NSD1 
represents a clinically useful biomarker that can be used to direct treatment intensity.
The NSD1 methyltransferase functions to monomethylate and dimethylate H3K36 (13). Mutations in 
NSD family proteins and dysregulation of methylation at H3K36 have both been linked to multiple human can-
cers (14). Recently, Bui and colleagues suggested that these epigenetic changes are responsible for the improved 
outcomes, citing increased sensitivity to cisplatin chemotherapy as a possible mechanism (11). However, using 
unsupervised hierarchical clustering of TCGA HNSCC DNA methylation data, we previously identified a 
Figure 1. Top 20 differentially mutated genes between never smokers and heavy smokers in the HPV-negative patient group. NSD1, CASP8, and COL11A1 
are mutated at significantly different frequencies after correction for the FDR. Fisher’s exact test was used for comparison, and FDR correction was done 
through Benjamini-Hochberg method.
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unique cluster comprising 13% of HPV-negative patients that contained either recurrent mutations in NSD1 or 
mutations in K36M in multiple H3 genes (10). Despite similar methylation profiles, NSD1- and H3K36M-mu-
tant tumors appeared markedly different from a prognostic perspective, with only patients with NSD1 mutation 
demonstrating favorable outcomes. H3K36M-mutant tumors behave similarly to the remainder of the tumors 
of the HPV-negative cohort, making methylation changes unlikely to be the sole source of treatment sensitivity.
In an effort to provide an alternative explanation for the improved survival observed in NSD1-mutant 
tumors, we compared the spectrum of  mutations in NSD1-mutant and NSD1 WT tumors. This revealed 
multiple genes encoding ECM components, including collagen (COL4A3, COL11A1, COL19A1, COL22A1, 
COL24A1) and laminin (LAMA1 and LAMA2), that were more frequently altered in NSD1-mutated tumors 
(Figure 4 and Supplemental Table 9). Further functional studies are necessary to come to definitive conclu-
sions regarding the role of  the ECM and NSD1 mutations in tumor aggressiveness.
Recently, Peri et al. reported that NSD1 mutation status predicted improved outcomes in laryngeal 
cancer using TCGA data; however, they did not identify a difference in prognosis in HPV-negative 
tumors in other head and neck subsites (12). That study did not integrate definitive viral transcript iden-
tification to classify tumor HPV status and instead relied on p16 and in situ hybridization testing, which 
was carried out on only a subset of  cases. This misclassifies a significant number of  tumors and partially 
obscures the analysis of  an HPV-negative cohort with previously unidentified HPV-positive samples (8). 
Tumor classification after HPV transcript analysis shows that only 2 of  the HPV-positive tumors are 
Figure 2. Overall survival comparison between NSD1-mutant and WT patients. Survival rate in (A) the HPV-negative TCGA HNSCC cohort and (B) an inde-
pendent cohort of 77 locally advanced HPV-negative oral cavity squamous cell carcinomas (OSCCs) from London Health Sciences Centre (LHSC).
 
Figure 3. Meta-analysis comparing overall survival stratified by NSD1 mutation status in HPV-negative tumors. IV, Inverse Variance; df, degrees of freedom.
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from the larynx, suggesting that anatomical location specification in Peri and colleagues’ analysis may 
have served to isolate HPV-negative tumor samples. Our multivariate analysis with definitive HPV sta-
tus assignment confirmed NSD1 mutation status as an independent prognostic factor in HPV-negative 
tumors regardless of  tumor site (Supplemental Table 6). Our validation cohort of  advanced oral cavity 
cancers as well as an additional cohort of  HPV-negative patients from Bui et al. (11) confirm generaliz-
ability of  the prognostic importance of  NSD1, greatly broadening the impact of  this finding.
Survival analysis of  TCGA’s HPV-positive and -negative HNSCC patient cohorts did not show a sig-
nificant difference between never smokers and heavy smokers. This is contrary to the reported prognostic 
significance of  smoking history as an independent variable in both HPV-positive and -negative disease in 
clinical trials (4, 15). We speculate that this observation may result from the heterogeneity of  treatment 
protocols within this cohort, which may obscure smaller survival differences.
After correction for multiple testing, significant differences in gene mutation frequency between nev-
er smokers and heavy smokers were identified but only in the HPV-negative cohort. A larger number of  
HPV-positive tumors may be necessary to better elucidate the mutational differences between never smok-
ers and heavy smokers within this group.
This study shows that the link between smoking and disease outcomes in HPV-negative HNSCCs may 
be more complex than previously believed. Mutations in NSD1 strongly predict improved overall survival, 
and genes involved with the ECM may be a possible mediator for this effect. Further studies are needed to 
understand the mechanisms of  the improved survival experienced by this subset of  patients.
Methods
Data collection. Patient data from TCGA, including level 3 DNA mutation packager calls data, CNAs, and 
merged clinical data sets, were retrieved using The Broad Institute’s Firehose databases (16). Firehose 
GISTIC2 copy number databases were used for CNA comparisons (17). The HPV status of  samples was 
assigned based on the detection of  viral transcripts by Bratman et al. (8). The resulting data sets included 
431 HPV-negative and 67 HPV-positive primary HNSCC samples with DNA mutation data and survival 
information for all but 1 of  the HPV-negative HNSCC cases. Patients were stratified as never smokers 
or heavy smokers (>20 pack year history) based on similar research in the literature (18–20). Patients 
with between 1 and 20 pack years (n = 59), patients with no smoking history information (n = 10), and 
Figure 4. Analysis of somatic SNVs between NSD1-mutant and WT HPV-negative HNSCC tumors. Genes associated with the ECM are highlighted in red. 
Fisher’s exact test was used for comparison, and FDR correction was done through Benjamini-Hochberg method.
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patients who were identified as current or former smokers but lacked pack year history information (n = 
90) were excluded. An additional data set from Stransky et al. (9) was used to assess the distribution of  
gene SNVs by smoking history.
Validation cohort. Tumor samples from patients with advanced T stage (T3–4) oral cavity cancers were 
obtained from 77 patients undergoing definitive primary surgery at LHSC. Matched blood was avail-
able for 74 patients (96%). Patient demographics and survival information were prospectively collected. 
Tumor cellularity of  greater than 70% was confirmed by pathologist review of  frozen sections. DNA 
was extracted from blood and tumor samples using Qiagen kits. The coding region of  the NSD1 gene 
was targeted for sequencing using an Illumina primer pool. Samples were processed at London Regional 
Genomics Centre (LRGC) on the Illumina MiSeq platform, with a targeted depth of  800×. FASTQ files 
were downloaded from LRGC and aligned to GRCh38 (GenBank accession: GCA_000001405.15, with 
decoy hs38d1) using BWA-MEM (v0.7.15). Duplicates were not marked due to the targeted nature of  
the data. Indel realignment and recalibration were performed using Genome Analysis Toolkit (GATK) 
(v3.7.0). For tumors with a matched normal, germline SNPs were called using GATK’s HaplotypeCaller 
(v3.7.0) and filtered for quality and read depth. Somatic SNVs were identified using MuTect (v1.1.7). For 
tumors without a matched normal, a panel of  normals (generated using 438 normal samples from TCGA 
HNSCC data set — BWA v0.7.12 with hs37d5, GATK v3.4.0, and MuTect v1.1.6, converted to GRCh38 
coordinates using Picard v2.7.1) was used to remove probable germline variants (along with the following 
filters: SNV passed quality control, had a minimum read depth of  50×, and was present in fewer than 4 
samples in the panel of  normals).
Statistics. TCGA exome sequencing data were analyzed using the maftools package (version 1.2.3) (21) 
within the Bioconductor framework in R statistical environment (version 3.4.0). The total mutation loads 
of  HPV-positive and HPV-negative patients were compared using Mann-Whitney U test. The correlation 
between total SNV count and number of  pack years was calculated using Spearman’s rank correlation, and 
2-tailed P values were reported. Synonymous mutation variants were excluded from downstream analyses. 
Fisher’s exact tests were used to identify the differentially mutated genes between never smokers and heavy 
smokers. Only genes that were mutated in at least 10% of  patients in at least 1 arm of  the comparison were 
evaluated. Derived P values were adjusted for FDR using the Benjamini-Hochberg method, and an FDR 
threshold of  0.1 was set for significance.
CNAs were compared for significant differences in deep deletions or large amplifications, as assigned 
by TCGA’s GISTIC2 analysis. Deep deletions were defined as deletions greater than the minimum arm-lev-
el deletion observed for the sample, and large amplifications as amplifications larger than the arm-level 
amplifications observed for the sample. Fisher’s exact tests were used for statistical testing of  differences of  
CNAs by smoking status in HPV-positive and -negative cohorts separately, and FDR adjustment was done 
as previously described.
The total mutation load, SNVs, and CNAs were similarly compared using Fisher’s exact tests with 
FDR adjustment to identify differences between NSD1-mutant and WT patients in the HPV-negative 
TCGA HNSCC cohort. The top 100 genes were defined as those with the largest differences in mutation 
frequency between NSD1-mutant and WT HPV-negative HNSCCs and were analyzed for pathway overrep-
resentation using the Reactome Knowledgebase online software (22).
Association of  NSD1 mutations with the top 25 mutated genes in HPV-negative HNSCC was done 
using Fisher’s exact test comparing the proportion of  samples with NSD1 mutation within a cohort with 
another gene mutation to the proportion of  NSD1-mutant samples in the entire HPV-negative TCGA 
cohort. FDR correction was done using the Benjamini-Hochberg method, and a threshold of  0.1 was set 
for significance.
χ2 Goodness of  fit and Mann-Whitney-Wilcoxon tests were used to compare the distribution of  clinical 
features between never smokers and heavy smokers in HPV-positive and -negative groups. The same anal-
ysis was applied to compare the distribution of  clinical features in the HPV-negative cohort, stratified by 
tumor NSD1 mutation status.
Overall survival outcomes were compared between never smokers and heavy smokers in both HPV-pos-
itive and HPV-negative subsets of  patients using the log-rank statistical approach. Analyses were performed 
using the survival package in R (v2.41-3) (23). For each of  the identified genes (NSD1, COL1A11, CASP8), a 
survival analysis was done using the log-rank test to compare outcomes in HPV-negative patients with muta-
tions to those without. A Cox regression model was used for multivariate analysis to assess the association of  
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each clinical variable, smoking status, and NSD1 mutation status with overall survival. The P values derived 
from the Wald test on the survival coefficients of  smoking history were reported, and the proportional hazards 
assumptions of  Cox models were tested, based on the scaled Schoenfeld residuals, to search for a significant 
relationship between residuals and time. Survival analysis was also carried out, stratifying by H3K36 muta-
tion status because Papillon-Cavanagh et al. (10) previously identified this in the HPV-negative TCGA cohort.
Somatic SNVs were filtered to remove nonfunctional (intronic/intergenic) variants before downstream 
analyses. Kaplan-Meier curves were constructed to compare overall survival for patients with NSD1-mutant 
versus NSD1 WT tumors. A Cox proportional hazards model was fit to carry out multivariate survival anal-
ysis for NSD1 mutation status with clinical covariates, including gender; age; smoking history (heavy, light, 
or never smoker); alcohol abuse (described history of  alcoholism or abuse by the patient or over 21 drinks 
per week); N-staging category; and margins (positive or negative). Multivariate analysis was performed 
via backward and forward stepwise analysis to attain the best model of  survival, and the final multivariate 
model of  survival with HRs associated with each variable was reported.
Survival data across cohorts was pooled and analyses carried out as above comparing patients with 
NSD1-mutant and NSD1 WT tumors. The pooled outcome was total mortality expressed as an HR. If  the 
studies did not quote HRs, we calculated the log10 HR and SEM from the available summary statistics or 
Kaplan-Meier curves, according to the methods proposed by Parmar and Tierney (24). For 1 source (12), 
we were unable to calculate the HR using these methods because the study did not report the observed 
events or the median and range of  follow-up. We therefore made the assumption that the 2-year mortal-
ity reported in the Kaplan-Meier curve was the observed death rate. We assessed the significance of  any 
discrepancies in the estimates of  the treatment effects from the different trials using Cochrane’s test for 
heterogeneity and the I2 statistic: I2 values over 50% indicated moderate to high heterogeneity, as described 
previously (25). We considered heterogeneity statistically significant if  the P value was less than 0.10 for 
the χ2 test. We combined HRs for survival data, using a fixed-effect model. We used Review Manager 5.3 
(The Cochrane Collaboration) to enter HR data into the meta-analysis using the inverse variance method.
Study approval. For the local oral cancer cohort, ethics approval was obtained from the University of  
Western Ontario Health Sciences Research Ethics Board (REB 16579). Informed consent was received 
from patients.
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